entertainment -WSS

entertainment

author：fashion 2025-08-11 11:45:59 - browse：85

What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.

For more on what we cover, here’s the news on Vertex; here’s more on Aduhelm; here’s the exit interview with Janet Woodcock; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： ‘Oppenheimer’ and the risks of AI in health care

WSS

Wildfire pollution widens asthma inequities on Long Island

Mitch McConnell episode has important public health takeaway

Sen. Paul opposes bill to ban Chinese biotechs

The high personal cost of affirmative action for Black doctors

What to expect as Trump is arraigned on his Jan 6. indictment

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

focus

entertainment

explore

Drug repurposing or repositioning? The language matters

Change Healthcare payments predicted restored March 15

Anesthesiologist group: stop taking Ozempic before surgery

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Adults seen as increasingly susceptible to measles

How one medical school became remarkably diverse

The problem with charging patients to message their doctors

Cancer drug shortages should be causing more outrage

Amylyx ALS drug fails large clinical trial

focus

Amylyx ALS drug fails large clinical trial

EQRx, failed developer of low

Change Healthcare payments predicted restored March 15

With psoriasis trial ahead, Alumis raises $259 million

How to bring more disabled researchers into academia

What the US credit downgrade means for the economy, your finances

hotspot

focus

hotspot

focus